MINDWALK HOLDINGS CORPORATION (HYFT) reported a standout fiscal year 2025, capped by record-setting fourth-quarter revenue and significant improvements in gross margins and adjusted EBITDA, driven by the exceptional growth of its BioStrand segment and a strategic pivot towards a bio-native AI platform.
- The company is executing a major strategic pivot, including the near-term completion of its Dutch subsidiary divestiture and an upcoming rebrand, to solidify its position as a bio-native AI platform integrating AI, connected data, and advanced lab research, with the LENSai platform powered by HYFT technology at its core.
- The BioStrand segment delivered outstanding results, growing over 180% year-over-year and achieving gross margins approaching 90%, which was a key driver in expanding the company's overall gross margins by 600 basis points to 55% for the full fiscal year and 64% in Q4.
- Secured a significant strategic partnership with a publicly traded multibillion-dollar technology company for oncology assets, valued at an initial $8 million with potential for $10 million. Additionally, the LENSai platform demonstrated breakthrough capabilities, including mapping antibody-antigen interactions with X-ray crystallography accuracy in hours and designing a GLP-1 peptide that matched or exceeded semaglutide.